SCHEMBL12436723

SCHEMBL12436723

CCC(=O)NC1CCC(C(C)=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.44
MTNR1B P49286 1/20 0.44
FASN P49327 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 4/20 0.41
NPSR1 Q6W5P4 1/20 0.40
EPHX2 P34913 1/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
SELL P14151 1/20 0.39
SELP P16109 1/20 0.39
SELE P16581 1/20 0.39
LMNA P02545 2/20 0.39
DRD2 P14416 1/20 0.39
EPHX1 P07099 1/20 0.38
SMYD3 Q9H7B4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22721998 1.00 MTNR1A (0.44) MTNR1AMTNR1BFASNSMN1; SMN2KMT2A
SCHEMBL256673 0.89
SCHEMBL11682924 0.89 MTNR1A (0.50) MTNR1AMTNR1BFASNSMN1; SMN2KMT2A
Hydrochloric Acid SCHEMBL28162204 0.87
SCHEMBL12436696 0.86 KMT2A (0.40) SMN1; SMN2KMT2ANPSR1EPHX2HPGD
SCHEMBL12513739 0.86 KMT2A (0.40) SMN1; SMN2KMT2ANPSR1EPHX2HPGD
SCHEMBL16383659 0.85 MTNR1A (0.45) MTNR1AMTNR1BFASNSMN1; SMN2KMT2A
SCHEMBL16892296 0.83 SELL (0.54) MTNR1AMTNR1BFASNSMN1; SMN2KMT2A
SCHEMBL31640052 0.83 FASN (0.44) MTNR1AMTNR1BFASNSMN1; SMN2KMT2A
SCHEMBL18214990 0.83 SELL (0.54) MTNR1AMTNR1BFASNSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B MTNR1A 63/4885MTNR1B 28/4885FASN 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.